ライフサイエンスコーパス: familial breast cancer

1 ons in BRCA2 have been linked to early-onset familial breast cancer.

2 nction variant in FANCM is a risk factor for familial breast cancer.

3 cer aggregation and, particularly, high-risk familial breast cancer.

4 e was identified based on its involvement in familial breast cancer.

5 covered genes may be important in explaining familial breast cancer.

6 J, thereby contributing to the prevention of familial breast cancers.

7 imately half the cases of autosomal dominant familial breast cancers.

8 a tumor suppressor that is mutated in 50% of familial breast cancers.

9 BRCA1 and BRCA2 account for the majority of familial breast cancers.

10 BRCA2 genes account for approximately 20% of familial breast cancers.

11 156 unrelated European-American females with familial breast cancer and 260 age-matched European-Amer

12 ns in BRCA1 account for approximately 45% of familial breast cancer and 90% of inherited breast/ovari

13 gham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registr

14 ve been previously reported in patients with familial breast cancer, and the PALB2 protein is a bindi

15 hese data show that methylation profiles for familial breast cancers are defined by the mutation stat

16 nsense (Y1853X) that have been identified in familial breast cancers, associated with Nmi and c-Myc b

17 d that rare mutations in BRCA2 predispose to familial breast cancer, but whether common variants at t

18 A significant proportion of familial breast cancers cannot be explained by mutations

19 An analysis of genotyping data from 8635 familial breast cancer cases and 6625 controls from diff

20 to show larger effect sizes in this study of familial breast cancer cases than in previous population

21 or BRCA1 and BRCA2 in the lymphocytes of non-familial breast cancer cases versus controls (BRCA1: 0.3

22 tations of BRCA2 account for about 10-30% of familial breast cancer cases.

23 hin BRCA1 and BRCA1 are responsible for most familial breast cancer cases.

24 g PALB2 mutations in 10/923 individuals with familial breast cancer compared with 0/1,084 controls (P

25 the etiological basis of either sporadic or familial breast cancer due to the loss or reduction of B

26 5R and Y1853X), that have been identified in familial breast cancers, failed to associate with ER-alp

27 A second, recently identified familial breast cancer gene, BRCA2, accounts for a propo

28 re, yet the fact that 5 FA genes are in fact familial breast cancer genes and FA gene mutations are f

29 Women affected by familial breast cancer had a highly significant excess o

30 Our understanding of the molecular basis of familial breast cancer has advanced significantly throug

31 A proportion of familial breast cancer has recently been shown by geneti

32 A substantial proportion of familial breast cancers have mutations within the BRCA2

33 To evaluate the contribution of PALB2 to familial breast cancer in the United States, we sequence

34 Their contribution to the development of familial breast cancer is less clear.

35 some of these findings to all patients with familial breast cancer is tempting.

36 ant BRCA1 allele (Mut.BRCA1) associated with familial breast cancer lacks OPN suppressor effects, bin

37 This region also possibly contains a familial breast cancer locus.

38 variants in women undergoing assessment for familial breast cancer may identify a distinct group of

39 med genome-wide DNA-methylation profiling on familial breast cancers (n = 33) to identify patterns of

40 work on management issues for patients with familial breast cancer not due to a detectable mutation

41 ovide a useful model system for the study of familial breast cancer pathogenesis and for elucidating

42 These associations were validated in a familial breast cancer patient cohort.

43 groups: familial breast cancer patients, non-familial breast cancer patients and age-matched cancer-f

44 the frequency of germ-line p53 mutations in familial breast cancer patients is 1% or less, but these

45 e identified a single p53 intron mutation in familial breast cancer patients that is present at eleva

46 RCA1, but not BRCA2, in the lymphocytes from familial breast cancer patients were found to be signifi

47 , we sequenced the HIN-1 coding region in 10 familial breast cancer patients with positive logarithm

48 of PALB2 by complete genomic sequencing for familial breast cancer patients with wild-type sequences

49 ene from constitutional genomic DNA of 1,144 familial breast cancer patients with wild-type sequences

50 germline CHEK2 missense alleles detected in familial breast cancer patients, 12 alleles had complete

51 and BRCA2 in lymphocytes from three groups: familial breast cancer patients, non-familial breast can

52 We screened individuals from 443 familial breast cancer pedigrees and 521 controls for AT

53 In addition, p53 alleles associated with familial breast cancer, previously classified as wild ty

54 MRI allows early detection of familial breast cancer regardless of patient age, breast

55 The majority of causative variants in familial breast cancer remain unknown.

56 r frequency of A133S in patients with higher familial breast cancer risk (P = 0.029; OR, 1.76; 95% CI

57 BRCA1 encodes a familial breast cancer suppressor that has a critical ro

58 The FA proteins and the familial breast cancer susceptibility gene products, BRC

59 pothesis that chromosome 8p12-p22 harbours a familial breast cancer susceptibility gene.

60 h as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest r

61 e allele of the BRCA1 gene contribute to the familial breast cancer syndrome.

62 Patients at high risk for familial breast cancer syndromes should be referred for

63 unt for the increased risk of early onset of familial breast cancer, whereas overexpression of the Er

64 gham Foundation Consortium for Research into Familial Breast Cancer, with ascertainment through famil

65 s; 1,550, sporadic breast cancer; and 1,505, familial breast cancer (without known BRCA1 or BRCA2 mut